Professor Paul Hofman, Director of IHU RespirERA, took part in the ESMO 2025 Congress held from October 17 to 21 in Berlin. This international event, a major reference in the field of oncology, brought together experts from around the world.
A major international event for cancer research
From October 17 to 21, 2025, Berlin hosted the ESMO Congress (European Society for Medical Oncology), one of the world’s largest gatherings dedicated to medical oncology. Experts from across the globe presented the latest advances in precision medicine, biomarkers, innovative therapies, and artificial intelligence applied to cancer care.
A key opportunity for scientific collaboration
IHU RespirERA’s participation in such a prestigious event highlights the importance of international scientific exchange in the fight against cancer. These congresses offer a valuable opportunity for the institute to share its research, strengthen partnerships, and draw inspiration from the latest therapeutic approaches presented by world leaders in oncology.
This presence also reinforces the position of IHU RespirERA as a recognized player in translational research and personalized medicine applied to respiratory diseases.
Promising advances for thoracic oncology
The themes showcased at ESMO 2025, including precision medicine, biomarkers, antibody-drug conjugates, and the use of circulating tumor DNA (ctDNA), directly align with the research conducted at IHU RespirERA on lung cancer.
These innovative approaches help to better characterize tumors, refine diagnoses, and personalize treatments. By integrating these advances, the institute continues to pursue its mission: to improve the understanding, diagnosis, and management of thoracic cancers in order to provide patients with more tailored and effective care.
